Bibliographic Details
| Title: |
Azithromycin Mechanisms of Action in CRS Include Epithelial Barrier Restoration and Type 1 Inflammation Reduction. |
| Authors: |
Renteria, Axel E., Valera, Fabiana C.P., Maniakas, Anastasios, Adam, Damien, Filali‐Mouhim, Ali, Ruffin, Manon, Mfuna, Leandra Endam, Brochiero, Emmanuelle, Desrosiers, Martin Y. |
| Source: |
Otolaryngology-Head & Neck Surgery; Oct2023, Vol. 169 Issue 4, p1055-1063, 9p |
| Abstract: |
Objective: Previous in vitro transcriptomic profiling suggests azithromycin exerts its effects in patients with chronic rhinosinusitis (CRS) via modulation of type 1 inflammation and restoration of epithelial barrier function. We wished to verify these postulated effects using in vitro models of epithelial repair and in vivo transcriptional profiling. Study Design: Functional effects of azithromycin in CRS were verified using in vitro models of wounding. The mechanism of the effect of azithromycin was assessed in vivo using transcriptomic profiling. Setting: Academic medical center. Methods: Effects of azithromycin on the speed of epithelial repair were verified in a wounding model using primary nasal epithelial cells (pNEC) from CRS patients. Nasal brushings collected pre‐and posttreatment during a placebo‐controlled trial of azithromycin for CRS patients unresponsive to surgery underwent transcriptomic profiling to identify implicated pathways. Results: Administration of azithromycin improved the wound healing rates in CRS pNECs and prevented the negative effect of Staphylococcus aureus on epithelial repair. In vivo, response to azithromycin was associated with downregulation in pathways of type 1 inflammation, and upregulation of pathways implicated in the restoration of the cell cycle. Conclusion: Restoration of healthy epithelial function may represent a major mode of action of azithromycin in CRS. In vitro models show enhanced epithelial repair, while in vivo transcriptomics shows downregulation of pathways type 1 inflammation accompanied by upregulation of DNA repair and cell‐cycle pathways. The maximal effect in patients with high levels of type 1‐enhanced inflammation suggests that azithromycin may represent a novel therapeutic option for surgery‐unresponsive CRS patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Otolaryngology-Head & Neck Surgery is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
